Reference priceUSD $630.00Original source price: INR 52,500.00. Converted estimates are available by currency selection.
| Brand | Mozobil |
|---|---|
| Manufacturer | Sanofi-Aventis Deutschland GmbH |
| Prescription required | Yes |
Mozobil 20mg/ml 1.2ml(Plerixafor)
PLERIXAFOR
Description
Mozobil 20mg/ml 1.2ml(Plerixafor) is a medicine catalog record in the MediPriceHub database. Active ingredient: PLERIXAFOR. Clinical use summary: See the Benefits field on this page for the product-specific indication or intended use. That field is kept separate from catalog metadata so users can distinguish clinical information from packaging information. Manufacturer or supplier: Sanofi-Aventis Deutschland GmbH. Therapeutic category: Medicine Library > Oncology Medicines > Non-Hodgkin's Lymphomas. Pack information: 20 / 1.2. Origin country or market: United States. This page is for medicine catalog reference only and should be read together with the approved prescribing information in the patient or buyer's country.Benefits
Mozobil is indicated in combination with filgrastim to mobilize hematopoietic stem cells (HSCs) to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) or multiple myeloma (MM).How to Use
Use PLERIXAFOR under the supervision of a qualified healthcare professional. Use it only according to the approved label and the instructions of a qualified healthcare professional. Do not start, stop, change the dose, split or crush a dosage form, mix with other medicines, or repeat a course unless the approved product information or a clinician confirms that it is appropriate. Check the local prescribing information for age limits, dose adjustments, missed-dose instructions, storage after opening or reconstitution, and monitoring requirements.Specification
Active ingredient: PLERIXAFOR. Pack size: 20 / 1.2. Pack unit: bottle. Manufacturer: Sanofi-Aventis Deutschland GmbH. Origin country: United States. Source category: Medicine Library > Oncology Medicines > Non-Hodgkin's Lymphomas. Availability, prescription status, storage, and exact approved use may vary by country. Check the local product information before clinical or procurement decisions.Side Effects
The available source record does not provide a clean, product-specific adverse-reaction list. Potential risks depend on the active ingredient, dose, route, treatment duration, and patient condition. Check the approved local prescribing information for the complete adverse-reaction profile, warnings, contraindications, and monitoring requirements. Seek urgent medical care for severe allergic symptoms, breathing difficulty, fainting, severe skin reactions, chest pain, serious bleeding, or rapidly worsening symptoms.This information is for reference only. Consult a qualified healthcare professional before using any medicine.